Date Title Description PDF
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
06 Oct 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 September and 5 October 2023 Download
02 Oct 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the third quarter of 2023 Download
29 Sep 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 22 September and 28 September 2023 Download
22 Sep 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 September and 21 September 2023 Download
15 Sep 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 8 September and 14 September 2023 Download

Pages

Date Title Description PDF
04 Apr 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the first quarter of 2019 Download
19 Mar 2019 R&D: new licenses, patents and registered trademarks ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia Download
26 Feb 2019 Informe Anual de Remuneraciones de los Consejeros ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors  Download
26 Feb 2019 Informe Anual de Gobierno Corporativo ROVI releases the 2018 Annual Corporate Governance Report Download
26 Feb 2019 Otros sobre gobierno corporativo The Company informs about the agreements adopted by the Board of Directors Download

Pages